Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 20-28 , January 2006

Radiation Therapy Combined With Hormone Therapy for Prostate Cancer

  • Andrew K. Lee, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Andrew K. Lee, MD, MPH, Department of Radiation Oncology, University of Texas-M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1202, Houston, TX 77030.

References 

  1. Zietman AL , Nakfoor BM , Prince EA , et al.   The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor (An in vitro and in vivo study) . Cancer J Sci Am . 1997;3:31–36
  2. Granfors T , Damber JE , Bergh A , et al.   Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma . Int J Radiat Oncol Biol Phys . 1997;39:1031–1036
  3. Joon DL , Hasegawa M , Sikes C , et al.   Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation . Int J Radiat Oncol Biol Phys . 1997;38:1071–1077
  4. Pollack A , Ashoori F , Sikes C , et al.   The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions . Int J Radiat Oncol Biol Phys . 2000;46:153–158
  5. Pollack A , Salem N , Ashoori F , et al.   Lack of prostate cancer radiosensitization by androgen deprivation . Int J Radiat Oncol Biol Phys . 2001;51:1002–1007
  6. Pilepich MV , Caplan R , Byhardt RW , et al.   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of Radiation Therapy Oncology Group Protocol 85-31) . J Clin Oncol . 1997;15:1013–1021
  7. Pilepich MV , Winter K , Lawton CA , et al.   Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 . Int J Radiat Oncol Biol Phys . 2005;61:1285–1290
  8. Bolla M , Collette L , Blank L , et al.   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) (A phase III randomised trial) . Lancet . 2002;360:103–106
  9. Bolla M , Gonzalez D , Warde P , et al.   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin . N Engl J Med . 1997;337:295–300
  10. Pilepich MV , Krall JM , al-Sarraf M , et al.   Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma (A randomized comparative trial of the Radiation Therapy Oncology Group) . Urology . 1995;45:616–623
  11. Pilepich MV , Winter K , John MJ , et al.   Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate . Int J Radiat Oncol Biol Phys . 2001;50:1243–1252
  12. Hanks GE , Pajak TF , Porter A , et al.  The Radiation Therapy Oncology Group Protocol 92-02   Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate . J Clin Oncol . 2003;21:3972–3978
  13. Roach M , DeSilvio M , Lawton C , et al.  Radiation Therapy Oncology Group 9413   Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression . J Clin Oncol . 2003;21:1904–1911
  14. D’Amico AV , Schultz D , Loffredo M , et al.   Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer . JAMA . 2000;284:1280–1283
  15. D’Amico AV , Manola J , Loffredo M , et al.   6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer (A randomized controlled trial) . JAMA . 2004;292:821–827
  16. Oefelein MG , Ricchuiti V , Conrad W , et al.   Skeletal fracture associated with androgen suppression induced osteoporosis (The clinical incidence and risk factors for patients with prostate cancer) . J Urol . 2001;166:1724–1728
  17. Daniell HW . Osteoporosis after orchiectomy for prostate cancer . J Urol . 1997;157:439–444
  18. Shahinian VB , Kuo YF , Freeman JL , et al.   Risk of fracture after androgen deprivation for prostate cancer . N Engl J Med . 2005;352:154–164
  19. Smith MR . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer . Urology . 2004;63:742–745
  20. Smith MR . Changes in body composition during hormonal therapy for prostate cancer . Clin Prostate Cancer . 2003;2:18–21
  21. Strum SB , McDermed JE , Scholz MC , et al.   Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade . Br J Urol . 1997;79:933–941
  22. Oefelein MG . Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting (Implications for dosing schedule and neoadjuvant study consideration) . J Urol . 1998;160:1685–1688
  23. Padula GD , Zelefsky MJ , Venkatraman ES , et al.   Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer . Int J Radiat Oncol Biol Phys . 2002;52:439–443
  24. Granfors T , Tomic R , Bergh A , et al.   After radiotherapy testosterone stimulation is unable to increase growth in the dunning R3327-PAP prostate tumour . Urol Res . 1999;27:357–361
  25. Crook J , Ludgate C , Malone S , et al.   Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer . Int J Radiat Oncol Biol Phys . 2004;60:15–23
  26. Iversen P , Tyrrell CJ , Kaisary AV , et al.   Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer (Results from two multicenter randomized trials at a median follow-up of 4 years) . Urology . 1998;51:389–396
  27. Iversen P . Quality of life issues relating to endocrine treatment options . Eur Urol . 1999;36(suppl 2):20–26
  28. Tyrrell CJ , Kaisary AV , Iversen P , et al.   A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer . Eur Urol . 1998;33:447–456
  29. Sanguineti G , Marcenaro M , Franzone P , et al.   Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy . Radiother Oncol . 2003;66:151–157
  30. Zelefsky MJ , Harrison A . Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer (Reducing the potential morbidity of therapy) . Urology . 1997;49:38–45
  31. Kucway R , Vicini F , Huang R , et al.   Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy . J Urol . 2002;167:2443–2447
  32. Selli C , Montironi R , Bono A , et al.   Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer . J Clin Pathol . 2002;55:508–513
  33. Steiner MS . Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival . Curr Urol Rep . 2000;1:7–8
  34. Steiner MS . Neoadjuvant androgen ablation before radical prostatectomy reduces positive margin rate, but has no effect on 36-month post-treatment biochemical failure . Curr Urol Rep . 2001;2:193–194
  35. Soloway MS , Pareek K , Sharifi R , et al.   Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer (5-year results) . J Urol . 2002;167:112–116
  36. Lee AK , Melancon A , Cheung R , et al.   Under-dosing of potential microscopic prostate cancer with IMRT after neoadjuvant hormonal therapy . Int J Radiat Oncol Biol Phys . 2004;60:S449
  37. Pollack A , Smith LG , von Eschenbach AC . External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era . Int J Radiat Oncol Biol Phys . 2000;48:507–512
  38. Zelefsky MJ , Fuks Z , Hunt M , et al.   High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer . J Urol . 2001;166:876–881
  39. Pollack A , Hanlon AL , Horwitz EM , et al.   Prostate cancer radiotherapy dose response (An update of the fox chase experience) . J Urol . 2004;171:1132–1136
  40. Pollack A , Zagars GK , Smith LG , et al.   Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer . J Clin Oncol . 2000;18:3904–3911
  41. Pollack A , Zagars GK , Starkschall G , et al.   Prostate cancer radiation dose response (Results of the M. D. Anderson phase III randomized trial) . Int J Radiat Oncol Biol Phys . 2002;53:1097–1105
  42. Nguyen KH , Horwitz EM , Hanlon AL , et al.   Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? . Int J Radiat Oncol Biol Phys . 2003;57:377–383

PII: S1053-4296(05)00047-0

doi: 10.1016/j.semradonc.2005.08.003

Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 20-28 , January 2006

Article Tools

* Image Usage & Resolution